Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lung Neoplasms 1Hodgkin Disease 1Carcinoma, Small Cell 1

Interventions

Carboplatin 369Pemetrexed 310pembrolizumab 303Cisplatin 244Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28tislelizumab 26cemiplimab 26avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × etoposide phosphate × Clear all
NCT01840579 2021-06-22

MK-3475-011

Merck Sharp & Dohme LLC

Phase 1 Completed
57 enrolled 60 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT00191139 2010-02-17

Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Completed
64 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡